Application of drebrin (DBN1) to preparing neurodegenerative disease diagnosis medicines

Abstract

The invention provides application of drebrin (DBN1) to preparing neurodegenerative disease diagnosis medicines. The application during diagnosis includes early diagnosis for neurodegenerative diseases and assessment for nerve injury severity degrees. The application has the advantages that diagnosis and assessment methods are carried out by means of determining the content of the DBN1 in blood plasma of peripheral blood, and the DBN1 of neurodegenerative disease patients is under obvious expression increase conditions; the DBN1 can be used as neurodegenerative disease marker proteins, the content of the DBN1 in blood of patients can be detected by the aid of enzyme-linked immunoassay quantitative reagent kits, accordingly, clinical symptoms can be assessed, whether the patients suffer from the neurodegenerative diseases or not can be judged before clinical examination changes, and nerve injury degrees can be monitored; detection means are integrally convenient, secondary injury on thepatients can be prevented, and accordingly the application has important clinical significance and important social and economic benefits in the aspects of prognosis, prevention and assessment for related diseases.

Description

technical field [0001] The invention relates to the field of medical biotechnology, in particular to the application of DBN1 protein in the preparation of diagnostic drugs for neurodegenerative diseases. Background technique [0002] Neurodegenerative diseases refer to degenerative diseases of the nervous system caused by neuron degeneration and apoptosis. According to clinical symptoms and pathological anatomy, they are divided into the following groups: [0003] 1. Syndromes of abnormal posture and movement, such as Parkinson's disease, multiple system atrophy [0004] 2. Progressive dementia syndromes, such as Alzheimer's disease, frontotemporal dementia [0005] 3. Progressive dementia with other neurological abnormalities, such as Huntington's chorea, corticobasal degeneration [0006] 4. Progressive ataxia syndrome, such as spinocerebellar ataxia [0007] 5. Slowly progressive muscle weakness and muscle wasting syndromes, such as motor neuron disease [0008] 6. S...

AI Technical Summary

Problems solved by technology

Detection of expression in brain or retinal tissue requires pathological specimens, and lumbar puncture is also required to obtain cerebrospinal fluid, which imposes a burden on patients and presents difficulties in clinical application

[0012] On the other hand, glaucoma, as a retinal neurodegenerative disease, can only be detected and evaluated by clinical examination, and there is currently no effective biomarker for diagnosis and evaluation

However, there are also some patients who cannot accurately observe the fundus and accurately assess the degree of nerve damage due to the turbidity of the refractive medium.

Images